- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
The Top 5 Biosimilars Articles for the Week of August 5
The Center for Biosimilars® recaps the top stories for the week of August 5, 2019.
Transcript
Hi, I’m Jaime Rosenberg for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of August 5, 2019.
Number 5: Concerns are rising that the marketplace may soon see the advent of authorized biologics, which are similar to authorized generics.
Number 4: Cancer Care Ontario is launching new educational materials as Canada awaits the arrival of additional anticancer biosimilars.
Number 3: A retrospective analysis of care delivery at Memorial Sloan Kettering Cancer Center showed that using subcutaneous rituximab resulted in substantial time savings.
Number 2: A new systematic review reported on real-world evidence on biosimilar etanercept in the treatment of inflammatory diseases.
Number 1: Momenta says that it is stopping work on its proposed adalimumab biosimilar after changes in the market related to Humira patent settlements.
Finally, last week, our e-newsletter asked whether you think that, if given the opportunity, Congress should make some changes to the existing Biologics Price Competition and Innovation Act.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
Newsletter
Where clinical, regulatory, and economic perspectives converge—sign up for Center for Biosimilars® emails to get expert insights on emerging treatment paradigms, biosimilar policy, and real-world outcomes that shape patient care.
Escaping the Void: All Things Biosimilars With Craig & G
August 5th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
